Formulated Delivery of Enzyme/Pro-Drug and Cytokine Gene Therapy to Promote Immune Reduction of Treated and Remote Tumors in Mouse Models of Prostate Cancer

2005 ◽  
Author(s):  
Pamela Russell
Keyword(s):  
Prostate Cancer ◽  
Gene Therapy ◽  
Mouse Models ◽  
Cytokine Gene ◽  
Cytokine Gene Therapy

Establishment and characterization of a rectal cancer model in mice: application to cytokine gene therapy

2002 ◽  
Vol 17 (6) ◽  
pp. 388-395 ◽  
Author(s):  
Yun Chen ◽  
King-Jen Chang ◽  
Lih-Hwa Hwang ◽  
Chiung-Nien Chen ◽  
Sheng-Hong Tseng
Keyword(s):  
Gene Therapy ◽  
Rectal Cancer ◽  
Cytokine Gene ◽  
Cancer Model ◽  
Cytokine Gene Therapy

IL-2 cytokine gene therapy of epithelial ovarian cancer

1999 ◽  
Vol 93 (4) ◽  
pp. S82-S83
Author(s):  
A ALHENDY ◽  
A MAGLIOCCO ◽  
T ALTEWEGERI ◽  
M ALHENDY ◽  
J CHEDRESE
Keyword(s):  
Ovarian Cancer ◽  
Gene Therapy ◽  
Epithelial Ovarian Cancer ◽  
Cytokine Gene ◽  
Cytokine Gene Therapy

scholarly journals Intravesical High Dose BCG Tokyo and Low Dose BCG Tokyo with GMCSF+IFN α Induce Systemic Immunity in a Murine Orthotopic Bladder Cancer Model

Biomedicines ◽  
2021 ◽  
Vol 9 (12) ◽  
pp. 1766
Author(s):  
Sin Mun Tham ◽  
Juwita N. Rahmat ◽  
Edmund Chiong ◽  
Qinghui Wu ◽  
Kesavan Esuvaranathan ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Bladder Cancer ◽  
Low Dose ◽  
Bladder Cancer Cell Line ◽  
High Dose ◽  
Cytokine Gene ◽  
Systemic Immunity ◽  
Bcg Therapy ◽  
Cytokine Gene Therapy

This study evaluates a short therapy schedule for bladder cancer using BCG Tokyo. BCG Tokyo was evaluated in vitro using bone marrow derived dendritic cells, neutrophils, RAW macrophages and the murine bladder cancer cell line, MB49PSA, and compared to other BCG strains. BCG Tokyo > BCG TICE at inducing cytokine production. In vivo, high dose (1 × 107 colony forming units (cfu)) and low dose (1 × 106 cfu) BCG Tokyo with and without cytokine genes (GMCSF + IFNα) were evaluated in C57BL/6J mice (n = 12–16 per group) with orthotopically implanted MB49PSA cells. Mice were treated with four instillations of cytokine gene therapy and BCG therapy. Both high dose BCG alone and low dose BCG combined with cytokine gene therapy were similarly effective. In the second part the responsive groups, mice (n = 27) were monitored by urinary PSA analysis for a further 7 weeks after therapy cessation. More mice were cured at day 84 than at day 42 confirming activation of the immune system. Cured mice resisted the re-challenge with subcutaneous tumors unlike naïve, age matched mice. Antigen specific T cells recognizing BCG, HY and PSA were identified. Thus, fewer intravesical instillations, with high dose BCG Tokyo or low dose BCG Tokyo with GMCSF + IFNα gene therapy, can induce effective systemic immunity.

Effects of Cytokine Gene Therapy on Prolonging Survival Time of Allografted Skin

2001 ◽  
Vol 16 (S1) ◽  
pp. S90-S90
Author(s):  
Zheng Jianghong ◽  
Gu Caizhi ◽  
Lin Zhihao
Keyword(s):  
Gene Therapy ◽  
Survival Time ◽  
Cytokine Gene ◽  
Cytokine Gene Therapy

scholarly journals Gmcsf and Ifnα gene therapy improves the response to BCG immunotherapy in a murine model of bladder cancer

2020 ◽  
Vol 16 (17) ◽  
pp. 1179-1188
Author(s):  
Sin Mun Tham ◽  
Ratha Mahendran ◽  
Edmund Chiong ◽  
Qing Hui Wu ◽  
Kesavan Esuvaranathan
Keyword(s):  
Gene Therapy ◽  
Immune Cell ◽  
Combined Therapy ◽  
Cytokine Gene ◽  
Cell Recruitment ◽  
Bcg Therapy ◽  
Cytokine Gene Therapy ◽  
Tumor Environment ◽  
Mrna Analysis ◽  
Immune Cell Recruitment

Aim: To develop a strategy to improve response to bacillus Calmette-Gueri (BCG) using cytokine gene therapy ( Gmcsf + Ifnα). Materials & methods: MB49-PSA tumor-bearing C57BL/6N mice were assigned into four groups: control; Gmcsf + Ifnα therapy; BCG therapy or combined therapy ( Gmcsf + Ifnα and BCG). In schedule 1, cytokine gene therapy was delivered before BCG therapy (eight instillations). In schedule 2, cytokine gene and BCG therapy were instilled alternatively (eight instillations). Tumors were analyzed by immunohistochemistry and mRNA analysis and urinary immune cells by flow cytometry. Results: Combined therapy in schedule 2 reduced tumor growth, increased immune cell recruitment and was associated with reduced inflammation when compared with BCG therapy. Conclusion: Alternating cytokine gene delivery with BCG therapy modulates the tumor environment increasing receptivity to BCG.

Cytokine gene therapy for experimental non small cell lung cancer (NSCLC)

1997 ◽  
Vol 56 ◽  
pp. 37
Author(s):  
A. Bout ◽  
C. Esandi ◽  
J.L. Noteboom ◽  
D.W. van Bekkum ◽  
D. Valerio
Keyword(s):  
Lung Cancer ◽  
Gene Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Cytokine Gene ◽  
Small Cell Lung ◽  
Cytokine Gene Therapy
Sign in / Sign up

Export Citation Format

Share Document